Nuvectis Pharma prices $100M public offering at $20 per share

Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced a public offering of 5,000,000 shares of common stock at $20.00 per share, with expected gross proceeds of $100 million, according to a press release from the clinical-stage biopharmaceutical company.

The company has also granted underwriters a 30-day option to purchase up to 750,000 additional shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to customary closing conditions.

Cantor is acting as sole book runner for the offering. H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners, a division of American Capital Partners, are acting as co-managers.

Nuvectis said it intends to use net proceeds to advance development programs for its pipeline candidates NXP100, NXP200, and NXP900, as well as for personnel hiring, capital expenditures, costs of operating as a public company, and general corporate purposes.

The shares are being offered pursuant to a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on February 13, 2026, and declared effective on February 20, 2026.

You May Also Be Interested In

• Zeo Energy Corp (ZEO) files $150M mixed shelf
• Alnylam to present ATTR and hypertension data at ESC 2026
• Mayfair Gold names two executives to advance Fenn-Gib project